시장보고서

상품코드

1507147

중도-중증 아토피 피부염(AD) : 시장 인사이트, 역학, 시장 예측(2034년)

Moderate to Severe Atopic Dermatitis (AD) - Market Insight, Epidemiology, and Market Forecast - 2034

발행일: On demand Report | 리서치사:

DelveInsight | 페이지 정보: 영문 200 Pages | 배송안내 : 2-10일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

샘플 요청 목록에 추가

세계의 주요 7개국(미국, 유럽 주요 5개국(EU5 : 프랑스·독일·이탈리아·스페인·영국), 일본)에서 중도·중증 아토피 피부염(AD)의 역학적 동향과 향후 시장 전망에 대해 분석했으며, 질환의 개요 및 시장의 기본 구조, 현재의 치료법과 미충족 요구, 환자 수의 동향 전망, 출시/임상시험중인 치료제의 개요, 세계 전체/각국의 시장 규모(2020-2034년), 주요 시장 촉진·억제요인 등의 정보를 정리하여 전해드립니다.

조사 개요

중도·중증 아토피 피부염 시장은 향후 수년간 이 질환에 대한 인식의 향상과 세계 전체의 의료비 증가에 의해 변화합니다.
기업 및 연구기관은 중도·중증 아토피 피부염 연구개발에 영향을 미칠 가능성이 있는 과제를 평가하고, 기회를 모색하는 작업을 하고 있습니다. 개발중인 치료법은 병태를 치료/개선하기 위한 신규 어프로치에 초점을 맞추고 있습니다.
주요 기업은 중도·중증 아토피 피부염의 치료법 개발에 관여하고 있습니다. 새로운 치료법의 출시는 중도·중증 아토피 피부염 시장에 큰 영향을 미칠 것입니다.
질환 병태의 심층 이해는 중도·중증 아토피 피부염의 신규 치료제 개발에도 기여합니다.
다른 개발 단계(제III상 및 제II상)에서 파이프라인 자산의 상세 분석 및 새로운 동향, 각 파이프라인 제품의 비교 분석(상세 임상 개요, 키 크로스 경쟁, 제품의 발매일·개발 활동 등 포함) 등의 정보가 연구개발 활동의 전체적인 시나리오를 식별하는 것으로 치료 포트폴리오에 관한 의사결정 프로세스에서 클라이언트를 지원합니다.

역학적 동향 : 주요 조사 결과
전제와 이론적 근거 : 주요 7개국
역학 시나리오 : 주요 7개국
- 중도·중증 아토피 피부염 : 주요 7개국에서 역학 시나리오(2020-2034년)
미국의 역학
- 미국내 중도·중증 아토피 피부염 역학 시나리오(2020-2034년)
유럽 주요 5개국(5EU)의 역학 : 국가별
- 독일의 역학
- 프랑스의 역학
- 이탈리아의 역학
- 스페인의 역학
- 영국의 역학
- 일본의 역학

제8장 치료 알고리즘, 현재의 치료, 의료 행위

중도·중증 아토피 피부염의 치료·관리 방법
중도·중증 아토피 피부염의 치료 알고리즘

제9장 미충족 요구

제10장 중도·중증 아토피 피부염 치료제의 주요 평가항목

제11장 출시 제품

주요 7개국의 출시 제품 리스트
약제 명칭 : 기업명
- 제품 개요
- 규제 마일스톤
- 기타 개발 활동
- 중요한 임상시험
- 중요한 임상시험 : 개요

제12장 새로운 치료제

키 크로스
약제 명칭 : 기업명
- 제품 개요
- 기타 개발 활동
- 임상 개발
- 안전성과 유효성
- 제품 개요

제13장 중도·중증 아토피 피부염 : 주요 7개국의 시장 분석

주요 조사 결과
중도·중증 아토피 피부염 시장 규모 : 주요 7개국
중도·중증 아토피 피부염 시장 규모 : 주요 7개국, 치료제별

제14장 속성 분석

제15장 주요 7개국 : 시장 전망

미국 시장 규모
- 미국의 중도·중증 아토피 피부염의 전체적인 시장 규모
- 미국의 중도·중증 아토피 피부염 시장 규모 : 치료제별
유럽 주요 5개국(EU5) 시장 : 시장 규모와 전망
독일 시장 규모
- 독일의 중도·중증 아토피 피부염의 전체적인 시장 규모
- 독일의 중도·중증 아토피 피부염 시장 규모 : 치료제별
프랑스 시장 규모
이탈리아 시장 규모
스페인 시장 규모
영국 시장 규모
- 영국의 중도·중증 아토피 피부염의 전체적인 시장 규모
- 영국의 중도·중증 아토피 피부염 시장 규모 : 치료제별
일본 시장 : 전망
- 일본 시장 규모

제16장 중도·중증 아토피 피부염의 액세스와 상환 개요

제17장 KOL의 견해

제18장 시장 촉진요인

제19장 시장 억제요인

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight 소개

KSA 24.07.10

DelveInsight's "Moderate to Severe Atopic Dermatitis (AD) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Moderate to Severe Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Moderate to Severe Atopic Dermatitis (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Moderate to Severe Atopic Dermatitis (AD) market report provides current treatment practices, emerging drugs, Moderate to Severe Atopic Dermatitis (AD) market share of the individual therapies, current and forecasted Moderate to Severe Atopic Dermatitis (AD) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Moderate to Severe Atopic Dermatitis (AD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2020-2034

Moderate to Severe Atopic Dermatitis (AD) Disease Understanding and Treatment Algorithm

The DelveInsight Moderate to Severe Atopic Dermatitis (AD) market report gives a thorough understanding of the Moderate to Severe Atopic Dermatitis (AD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Moderate to Severe Atopic Dermatitis (AD).

Treatment

It covers the details of conventional and current medical therapies available in the Moderate to Severe Atopic Dermatitis (AD) market for the treatment of the condition. It also provides Moderate to Severe Atopic Dermatitis (AD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Moderate to Severe Atopic Dermatitis (AD) Epidemiology

The Moderate to Severe Atopic Dermatitis (AD) epidemiology division provide insights about historical and current Moderate to Severe Atopic Dermatitis (AD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Moderate to Severe Atopic Dermatitis (AD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Moderate to Severe Atopic Dermatitis (AD) Epidemiology

The epidemiology segment also provides the Moderate to Severe Atopic Dermatitis (AD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Moderate to Severe Atopic Dermatitis (AD) Drug Chapters

Drug chapter segment of the Moderate to Severe Atopic Dermatitis (AD) report encloses the detailed analysis of Moderate to Severe Atopic Dermatitis (AD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Moderate to Severe Atopic Dermatitis (AD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Moderate to Severe Atopic Dermatitis (AD) treatment.

Moderate to Severe Atopic Dermatitis (AD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Moderate to Severe Atopic Dermatitis (AD) treatment.

Moderate to Severe Atopic Dermatitis (AD) Market Outlook

The Moderate to Severe Atopic Dermatitis (AD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Moderate to Severe Atopic Dermatitis (AD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Moderate to Severe Atopic Dermatitis (AD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Moderate to Severe Atopic Dermatitis (AD) market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Moderate to Severe Atopic Dermatitis (AD) market in 7MM.

The United States Market Outlook

This section provides the total Moderate to Severe Atopic Dermatitis (AD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Moderate to Severe Atopic Dermatitis (AD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Moderate to Severe Atopic Dermatitis (AD) market size and market size by therapies in Japan is also mentioned.

Moderate to Severe Atopic Dermatitis (AD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Moderate to Severe Atopic Dermatitis (AD) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Moderate to Severe Atopic Dermatitis (AD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Moderate to Severe Atopic Dermatitis (AD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Moderate to Severe Atopic Dermatitis (AD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Moderate to Severe Atopic Dermatitis (AD) emerging therapies.

Reimbursement Scenario in Moderate to Severe Atopic Dermatitis (AD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Moderate to Severe Atopic Dermatitis (AD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Moderate to Severe Atopic Dermatitis (AD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Moderate to Severe Atopic Dermatitis (AD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

The report covers the descriptive overview of Moderate to Severe Atopic Dermatitis (AD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Moderate to Severe Atopic Dermatitis (AD) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Moderate to Severe Atopic Dermatitis (AD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Moderate to Severe Atopic Dermatitis (AD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Moderate to Severe Atopic Dermatitis (AD) market

Report Highlights:

In the coming years, Moderate to Severe Atopic Dermatitis (AD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Moderate to Severe Atopic Dermatitis (AD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Moderate to Severe Atopic Dermatitis (AD). Launch of emerging therapies will significantly impact the Moderate to Severe Atopic Dermatitis (AD) market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Moderate to Severe Atopic Dermatitis (AD)
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Moderate to Severe Atopic Dermatitis (AD) Report Insights

Patient Population
Therapeutic Approaches
Moderate to Severe Atopic Dermatitis (AD) Pipeline Analysis
Moderate to Severe Atopic Dermatitis (AD) Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Moderate to Severe Atopic Dermatitis (AD) Report Key Strengths

11 Years Forecast
7MM Coverage
Moderate to Severe Atopic Dermatitis (AD) Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Moderate to Severe Atopic Dermatitis (AD) Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions:

Market Insights:

What was the Moderate to Severe Atopic Dermatitis (AD) market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Moderate to Severe Atopic Dermatitis (AD) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Moderate to Severe Atopic Dermatitis (AD) market size during the forecast period (2024-2034)?
At what CAGR, the Moderate to Severe Atopic Dermatitis (AD) market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Moderate to Severe Atopic Dermatitis (AD) market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Moderate to Severe Atopic Dermatitis (AD) market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Moderate to Severe Atopic Dermatitis (AD)?
What is the historical Moderate to Severe Atopic Dermatitis (AD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Moderate to Severe Atopic Dermatitis (AD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Moderate to Severe Atopic Dermatitis (AD)?
Out of all 7MM countries, which country would have the highest prevalent population of Moderate to Severe Atopic Dermatitis (AD) during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Moderate to Severe Atopic Dermatitis (AD) treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Moderate to Severe Atopic Dermatitis (AD) in the USA, Europe, and Japan?
What are the Moderate to Severe Atopic Dermatitis (AD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Moderate to Severe Atopic Dermatitis (AD)?
How many therapies are developed by each company for Moderate to Severe Atopic Dermatitis (AD) treatment?
How many are emerging therapies in mid-stage, and late stage of development for Moderate to Severe Atopic Dermatitis (AD) treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Moderate to Severe Atopic Dermatitis (AD) therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Moderate to Severe Atopic Dermatitis (AD) and their status?
What are the key designations that have been granted for the emerging therapies for Moderate to Severe Atopic Dermatitis (AD)?
What are the global historical and forecasted market of Moderate to Severe Atopic Dermatitis (AD)?

Reasons to buy:

The report will help in developing business strategies by understanding trends shaping and driving the Moderate to Severe Atopic Dermatitis (AD) market
To understand the future market competition in the Moderate to Severe Atopic Dermatitis (AD) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Moderate to Severe Atopic Dermatitis (AD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Moderate to Severe Atopic Dermatitis (AD) market
To understand the future market competition in the Moderate to Severe Atopic Dermatitis (AD) market

1. Key Insights

2. Executive Summary of Moderate to Severe Atopic Dermatitis (AD)

3. Competitive Intelligence Analysis for Moderate to Severe Atopic Dermatitis (AD)

4. Moderate to Severe Atopic Dermatitis (AD): Market Overview at a Glance

4.1. Moderate to Severe Atopic Dermatitis (AD) Total Market Share (%) Distribution in 2020
4.2. Moderate to Severe Atopic Dermatitis (AD) Total Market Share (%) Distribution in 2034

5. Moderate to Severe Atopic Dermatitis (AD): Disease Background and Overview

5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Patient Journey

7. Moderate to Severe Atopic Dermatitis (AD) Epidemiology and Patient Population

7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
- 7.3.1. Moderate to Severe Atopic Dermatitis (AD) Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
- 7.4.1. Moderate to Severe Atopic Dermatitis (AD) Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
- 7.5.1. Germany Epidemiology
  - 7.5.1.1. Moderate to Severe Atopic Dermatitis (AD) Epidemiology Scenario in Germany (2020-2034)
- 7.5.2. France Epidemiology
  - 7.5.2.1. Moderate to Severe Atopic Dermatitis (AD) Epidemiology Scenario in France (2020-2034)
- 7.5.3. Italy Epidemiology
  - 7.5.3.1. Moderate to Severe Atopic Dermatitis (AD) Epidemiology Scenario in Italy (2020-2034)
- 7.5.4. Spain Epidemiology
  - 7.5.4.1. Moderate to Severe Atopic Dermatitis (AD) Epidemiology Scenario in Spain (2020-2034)
- 7.5.5. United Kingdom Epidemiology
  - 7.5.5.1. Moderate to Severe Atopic Dermatitis (AD) Epidemiology Scenario in the United Kingdom (2020-2034)
- 7.5.6. Japan Epidemiology
  - 7.5.6.1. Moderate to Severe Atopic Dermatitis (AD) Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Moderate to Severe Atopic Dermatitis (AD) Treatment and Management
8.2. Moderate to Severe Atopic Dermatitis (AD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Moderate to Severe Atopic Dermatitis (AD) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Pivotal Clinical Trials
- 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross
12.2. Drug Name: Company Name
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Safety and Efficacy
- 12.2.5. Product Profile